Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IDH2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IDH2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IDH2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IDH2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IDH2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IDH2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IDH2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IDH2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IDH2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19026521 | Liver | Cirrhotic | secondary alcohol metabolic process | 75/4634 | 147/18723 | 5.62e-12 | 3.91e-10 | 75 |
GO:000675312 | Liver | Cirrhotic | nucleoside phosphate metabolic process | 190/4634 | 497/18723 | 1.10e-11 | 6.96e-10 | 190 |
GO:000911712 | Liver | Cirrhotic | nucleotide metabolic process | 187/4634 | 489/18723 | 1.55e-11 | 9.63e-10 | 187 |
GO:000606612 | Liver | Cirrhotic | alcohol metabolic process | 141/4634 | 353/18723 | 1.57e-10 | 8.03e-09 | 141 |
GO:00060995 | Liver | Cirrhotic | tricarboxylic acid cycle | 19/4634 | 30/18723 | 8.57e-06 | 1.27e-04 | 19 |
GO:004364811 | Liver | Cirrhotic | dicarboxylic acid metabolic process | 43/4634 | 96/18723 | 1.42e-05 | 1.97e-04 | 43 |
GO:00091654 | Liver | Cirrhotic | nucleotide biosynthetic process | 89/4634 | 254/18723 | 1.45e-04 | 1.40e-03 | 89 |
GO:00060815 | Liver | Cirrhotic | cellular aldehyde metabolic process | 28/4634 | 60/18723 | 1.83e-04 | 1.71e-03 | 28 |
GO:004426211 | Liver | Cirrhotic | cellular carbohydrate metabolic process | 97/4634 | 283/18723 | 1.89e-04 | 1.76e-03 | 97 |
GO:19012934 | Liver | Cirrhotic | nucleoside phosphate biosynthetic process | 89/4634 | 256/18723 | 1.97e-04 | 1.82e-03 | 89 |
GO:19049502 | Liver | Cirrhotic | negative regulation of establishment of protein localization | 49/4634 | 131/18723 | 8.50e-04 | 6.15e-03 | 49 |
GO:0042063 | Liver | Cirrhotic | gliogenesis | 98/4634 | 301/18723 | 1.28e-03 | 8.60e-03 | 98 |
GO:0051224 | Liver | Cirrhotic | negative regulation of protein transport | 47/4634 | 127/18723 | 1.39e-03 | 9.27e-03 | 47 |
GO:00510514 | Liver | Cirrhotic | negative regulation of transport | 141/4634 | 470/18723 | 5.06e-03 | 2.62e-02 | 141 |
GO:0072350 | Liver | Cirrhotic | tricarboxylic acid metabolic process | 8/4634 | 14/18723 | 9.65e-03 | 4.35e-02 | 8 |
GO:000609122 | Liver | HCC | generation of precursor metabolites and energy | 340/7958 | 490/18723 | 4.04e-34 | 2.85e-31 | 340 |
GO:000906012 | Liver | HCC | aerobic respiration | 147/7958 | 189/18723 | 3.13e-23 | 6.61e-21 | 147 |
GO:004533312 | Liver | HCC | cellular respiration | 171/7958 | 230/18723 | 6.35e-23 | 1.26e-20 | 171 |
GO:001598022 | Liver | HCC | energy derivation by oxidation of organic compounds | 221/7958 | 318/18723 | 1.02e-22 | 1.86e-20 | 221 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IDH2 | SNV | Missense_Mutation | rs770548230 | c.1054N>C | p.Thr352Pro | p.T352P | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-B6-A40B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | rs770548230 | c.1054N>C | p.Thr352Pro | p.T352P | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.985) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
IDH2 | deletion | Frame_Shift_Del | novel | c.1182delN | p.Phe394LeufsTer18 | p.F394Lfs*18 | P48735 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
IDH2 | SNV | Missense_Mutation | rs781481805 | c.1247N>T | p.Ala416Val | p.A416V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IDH2 | SNV | Missense_Mutation | rs267606870 | c.418C>T | p.Arg140Trp | p.R140W | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(1) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | | c.1322N>C | p.Ile441Thr | p.I441T | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.948) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IDH2 | SNV | Missense_Mutation | rs201173543 | c.140N>T | p.Ala47Val | p.A47V | P48735 | protein_coding | tolerated_low_confidence(0.13) | benign(0.012) | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | rs781481805 | c.1247N>T | p.Ala416Val | p.A416V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.43) | TCGA-AA-A01Z-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IDH2 | SNV | Missense_Mutation | | c.992N>T | p.Thr331Met | p.T331M | P48735 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IDH2 | SNV | Missense_Mutation | | c.560N>T | p.Asp187Val | p.D187V | P48735 | protein_coding | deleterious_low_confidence(0.01) | benign(0.117) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | AG-881 | | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | AGI-6780 | | 23558173 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | enasidenib | ENASIDENIB | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Enasidenib | ENASIDENIB | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | VENETOCLAX | VENETOCLAX | 30725494 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Enasidenib | ENASIDENIB | 28588020,28193778 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | ENASIDENIB | ENASIDENIB | 28588020,28193778 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | inhibitor | 404859110 | | |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Venetoclax | VENETOCLAX | 27520294 |
3418 | IDH2 | CLINICALLY ACTIONABLE, ENZYME | | Venetoclax | VENETOCLAX | |